Neurology
Drug reverses autism-like brain changes in adult mice within hours, <a href="https://healthylife7.com/39-popular-sweeteners-can-alter-key-gut-bacteria-lab-study-finds/" title="39 popular sweeteners can alter key gut bacteria, lab study finds“>study finds
Study links maternal inflammation to lasting autism-like traits in mice and identifies a brain pathway that may offer a new therapeutic target
Credit: AdobeStock
July 23, 2026
5 min read
Key Takeaways
- In mice exposed to inflammation during pregnancy, the offspring developed lasting autism-like brain and behavior changes, suggesting that early inflammation can disrupt brain development in ways that persist into adulthood.
- A single dose of rapamycin rapidly improved several of those changes, including brain overactivity, seizure risk, sensory sensitivity, repetitive behaviors and abnormal brain functional network organization.
- The findings suggest that some autism-related brain changes may still be treatable in adulthood, pointing to possible therapeutic approaches that target the underlying pathway rather than only symptoms.
The effects of rapamycin are temporary, and repeated dosing loses efficacy, making rapamycin, itself, an unlikely candidate as a broadly-used treatment
A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring, but also that those brain and behavior effects may be rapidly but temporarily reversible in adulthood with a short-term dose of the immunosuppressive drug rapamycin
Even mild inflammation during mid-pregnancy has been shown to result in offspring autism-like symptoms, abnormal brain growth, seizures and heightened sensitivity to everyday sensory input that persists into adulthood. In the study published in the journal Nature Communications, UCLA researchers found that a single dose of the drug rapamycin significantly improved brain signaling and behavior symptoms in these offspring within about two hours, a time too short to correct underlying physical brain changes created by the maternal inflammation.
The study did not identify rapamycin as ary effects and potential for toxicity from repeated doses. Instead, researchers said the drug’s effects revealed new therapeutic targets for the development of future treatments
“The level of functional normalization achieved over this short time suggests new mechanisms by which possible treatments may act,” said the study’s senior author Dr. Harley Kornblum, director of the UCLA Intellectual and Developmental Disabilities Research Center in the Semel Institute for Neuroscience and Human Behavior. “It suggests the adult brain may be more adaptable than we assumed, even when the underlying structural changes from early development are still there. This points us toward the brain’s functional circuitry, not just its physical structure, as a target for future treatment approaches.”
Previous studies have shown that offspring of mothers who experience inflammation while pregnant have a higher likelihood of developing autism-associated traits such as repetitive behaviors and difficulty with social interaction, as well as brain overgrowth and disrupted sensory processing that continue into adulthood.
Additionally, rapamycin has been shown in previous mouse autism studies to improve symptoms by suppressing an overactive pathway that signals cell growth and proliferation, known as the mTOR pathway
What was less clear was whether these brain changes could still be modifiable in adulthood, and whether rapamycin’s benefits came from long-term structural repair or faster functional changes
In this study, researchers exposed pregnant mice to a mild inflammatory trigger early in gestation at a dose that was too low to make the mothers significantly ill. The resulting offspring went on to develop chronic brain and body-wide inflammation, mild brain overgrowth, overactive cell-signaling in the mTOR pathway, disorganized brain functional network connectivity and behaviors associated with autism
When researchers gave adult offspring a single dose of rapamycin, they found rapid improvement across nearly every measure: neurons that had been firing abnormally calmed down, susceptibility to seizures dropped, brain regions that had been miscommunicating reorganized into more typical patterns and repetitive behaviors and sensory over-responsivity eased. These changes occurred within roughly two hours, which was too quick to be explained by the kind of physical rewiring of brain synapses that typically takes longer.
“These results reframe how autism-associated symptoms might be treated. If the adult brain remains capable of functional normalization, then some features of autism may be successfully addressed without needing to correct underlying structural differences,” said the paper’s first author Dr. Janel Le Belle, an associate professor in the UCLA Department of Neurosurgery
To understand the mechanisms of rapid rapamycin effects, researchers examined gene activity in brain cells before and after treatment. They found that rapamycin reversed abnormal expression of genes tied to autism, epilepsy and ion channel function, particularly in excitatory neurons, suggesting the drug works by quickly rebalancing brain cell excitability rather than by repairing structural brain differences
The findings suggest that mTOR pathway activity, brain network organization and neuronal excitation levels as potential targets for future therapies aimed at specific autism symptoms such as sensory over-responsivity, a common but difficult-to-treat symptom of autism
Co-senior author and professor in the UCLA Department of Neurosurgery, Dr. Neil Harris, cautioned that they also found the treatment effects to be temporary and that daily dosing produced tolerance over several weeks. This, along with rapamycin’s high potential for toxicity and the fact that these studies were performed in mice, makes it unsuitable for broad use in humans
“This points toward new therapeutic targets like sensory circuit neuromodulation or balancing neuronal inhibition and excitation, rather than toward rapamycin itself as a treatment,” Harris said
Funding for the study was provided by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the UCLA Brain Injury Research Center, the UCLA Intellectual and Developmental Disabilities Research Center, the National Institutes of Health, the Simons Foundation for Autism Research, Autism Speaks, and the UCLA Center for Autism Research and Treatment.
View All News & Insights
Related Content
Articles:
Services:
Physician
Team Members
Neil Harris, PhDNeurosurgery
Janel Le Belle, PhD
Media Contact
Will Houston
[email protected]
Share:
Related Articles
June 24, 2026
June 23, 2026
June 17, 2026
View all Related Articles
